Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zhang, Pengfei | - |
dc.contributor.author | Xiao, Yufen | - |
dc.contributor.author | Sun, Xue | - |
dc.contributor.author | Lin, Xiaoning | - |
dc.contributor.author | Koo, Seyoung | - |
dc.contributor.author | Yaremenko, Alexey V. | - |
dc.contributor.author | Qin, Duotian | - |
dc.contributor.author | Kong, Na | - |
dc.contributor.author | Farokhzad, Omid C. | - |
dc.contributor.author | Tao, Wei | - |
dc.date.accessioned | 2024-05-02T02:30:34Z | - |
dc.date.available | 2024-05-02T02:30:34Z | - |
dc.date.issued | 2023-03 | - |
dc.identifier.issn | 2666-6359 | - |
dc.identifier.issn | 2666-6340 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/erica/handle/2021.sw.erica/118938 | - |
dc.description.abstract | With the integration of nanotechnology into the medical field at large, great strides have been made in the development of nanomedicines for tackling different diseases, including cancers. To date, various cancer nanomedicines have demonstrated success in preclinical studies, improving therapeutic outcomes, prolonging survival, and/or decreasing side effects. However, the translation from bench to bedside remains challenging. While a number of nanomedicines have entered clinical trials, only a few have been approved for clinical applications. In this review, we highlight the most recent progress in cancer nanomedicine, discuss current clinical advances and challenges for the translation of cancer nanomedicines, and provide our viewpoints on accelerating clinical translation. We expect this review to benefit the future development of cancer nanotherapeutics specifically from the clinical perspective. © 2022 Elsevier Inc. | - |
dc.format.extent | 21 | - |
dc.publisher | Cell Press | - |
dc.title | Cancer nanomedicine toward clinical translation: Obstacles, opportunities, and future prospects | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1016/j.medj.2022.12.001 | - |
dc.identifier.scopusid | 2-s2.0-85144964493 | - |
dc.identifier.wosid | 000987452600001 | - |
dc.identifier.bibliographicCitation | Med, v.4, no.3, pp 147 - 167 | - |
dc.citation.title | Med | - |
dc.citation.volume | 4 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 147 | - |
dc.citation.endPage | 167 | - |
dc.type.docType | 정기 학술지(Review) | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | esci | - |
dc.subject.keywordAuthor | cancer nanomedicine | - |
dc.subject.keywordAuthor | clinical translation | - |
dc.subject.keywordAuthor | current status | - |
dc.subject.keywordAuthor | future prospects | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S2666634022005177?via%3Dihub | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
55 Hanyangdeahak-ro, Sangnok-gu, Ansan, Gyeonggi-do, 15588, Korea+82-31-400-4269 sweetbrain@hanyang.ac.kr
COPYRIGHT © 2021 HANYANG UNIVERSITY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.